Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multiple Ascending Intradermal Dose Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Next Previous
Trial Profile

A Phase 1 Multiple Ascending Intradermal Dose Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP 2390 (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Astellas Pharma Global Development

Most Recent Events

  • 15 Aug 2022 According to clinical trials.gov, protocol amended as timeframe has been changed from 5years to 63 weeks
  • 18 Jan 2022 Planned End Date changed from 28 Feb 2023 to 31 Dec 2026.
  • 18 Jan 2022 Planned primary completion date changed from 28 Feb 2023 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top